Age-related maculopathy: pathogenetic features and new treatment modalities.
about
Dietary analysis and patterns of nutritional supplement use in normal and age-related macular disease affected subjects: a prospective cross-sectional studyToday and future of age-related macular degenerationEfflux protein expression in human stem cell-derived retinal pigment epithelial cellsPerception of very small visual stimuli in the fovea: normative data for the Rarebit Foveal Test.The Amsler chart is of doubtful value in retinal screening for early laser therapy of subretinal membranes. The West London Survey.Effect of flavone on the ocular blood flow and formation of choroidal neovascularizationAge-related macular degeneration and nutritional supplementation: a review of randomised controlled trials.Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept.Nordic research in ophthalmology.2-Phenyl-APB-144-Induced Retinal Pigment Epithelium Degeneration and Its Underlying MechanismsOxidative stress-mediated NFκB phosphorylation upregulates p62/SQSTM1 and promotes retinal pigmented epithelial cell survival through increased autophagy.Retinal photodamage by endogenous and xenobiotic agents.Preventive effect of Vaccinium uliginosum L. extract and its fractions on age-related macular degeneration and its action mechanisms.Autophagy regulating kinases as potential therapeutic targets for age-related macular degeneration.p62/sequestosome 1 as a regulator of proteasome inhibitor-induced autophagy in human retinal pigment epithelial cells.The PI3K-PTEN tug-of-war, oxidative stress and retinal degeneration.Involvement of transcription initiation factor IIB in the light-induced death of rat retinal ganglion cells in vivo.Filtering blue light reduces light-induced oxidative stress, senescence and accumulation of extracellular matrix proteins in human retinal pigment epithelium cells.Visual acuity and central retinal thickness: fulfilment of retreatment criteria for recurrent neovascular AMD in routine clinical care.
P2860
Q24800227-59BBA24D-E096-4CE5-9687-498102B106D5Q26865643-A76772EC-0923-427F-A308-67157CEE50B7Q28478917-F943C2BA-0EC8-451E-8469-7DE3EEFE63EDQ31032823-01ACCB4C-3181-4B1F-85A1-128AC827AD8CQ31058996-6823331C-FC8D-4B79-8145-ADA7881EB988Q34254456-E68110C7-03C2-4E9F-9C64-71E57DBDCC14Q34536731-9932FDD2-674D-4F91-8F68-12DE222AAD44Q34642583-FF5C53D9-BE8B-414D-8B9D-73DD4D352A19Q35594451-5C4EF8B4-8655-48AD-A504-7256303E4859Q36274458-81C92D29-3A0F-4CB3-9EFD-0D6F00540300Q36286185-1529D1EF-9371-44EE-8EA7-831F7CF63AA1Q38009850-528CC423-DCF4-4AF7-8F83-9D11F47BDC17Q38818001-68A17E26-0EE7-4811-9AF0-4F81D76ED9BBQ39512471-3E5DD283-631E-460A-8182-0B08AA90B27CQ39672441-397FA62F-CA3D-4BF4-89EE-B0EC9B952B37Q41460864-CB371779-535E-44C4-BC9F-79FC78BD2E0EQ43954509-EC4CA838-854E-49CE-9B0B-465C3F1452C4Q50275844-0681DC75-2D9F-4C95-946A-CC31D76BB304Q50672879-0D14D88B-FC52-49A2-915E-5B4CAA5DDBDE
P2860
Age-related maculopathy: pathogenetic features and new treatment modalities.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Age-related maculopathy: pathogenetic features and new treatment modalities.
@ast
Age-related maculopathy: pathogenetic features and new treatment modalities.
@en
Age-related maculopathy: pathogenetic features and new treatment modalities.
@nl
type
label
Age-related maculopathy: pathogenetic features and new treatment modalities.
@ast
Age-related maculopathy: pathogenetic features and new treatment modalities.
@en
Age-related maculopathy: pathogenetic features and new treatment modalities.
@nl
prefLabel
Age-related maculopathy: pathogenetic features and new treatment modalities.
@ast
Age-related maculopathy: pathogenetic features and new treatment modalities.
@en
Age-related maculopathy: pathogenetic features and new treatment modalities.
@nl
P1433
P1476
Age-related maculopathy: pathogenetic features and new treatment modalities.
@en
P2093
Peep V Algvere
Stefan Seregard
P304
P356
10.1034/J.1600-0420.2002.800204.X
P577
2002-04-01T00:00:00Z